Lenvatinib resistance was accompanied by aberrant cholesterol metabolism and lipid raft activation. ATP-binding cassette transporter B1 (ABCB1) was activated by EGFR in a lipid raft-dependent manner, which significantly enhanced the exocytosis of lenvatinib to mediate resistance.
[Cancer Research]